Skip to main content
. 2001 Mar 15;15(6):710–723. doi: 10.1101/gad.194101

Figure 5.

Figure 5

MBD2 requirement for MeCP1 formation. (a) MeCP1 from liver nuclear extracts is visualized as two different complexes (I and II) in a band shift assay using the methylated form of the probe CG11 (MeCG11). Lanes 1–3, wild-type nuclear extract; lanes 4–6, Mbd2(−/−) nuclear extract. Complex I is the major band produced in wild-type nuclei (lanes 1–3) but is absent in Mbd2(−/−) nuclei (lanes 4–6). An MBD2-specific antibody (S923) was added to lanes 2 and 5, while an antibody that recognizes both MBD2 and MBD3 (R593) was added to lanes 3 and 6. (b) Three complexes (I, II, and III) are visible in nuclear extracts derived from fibroblasts, although complex III is obscured in lanes 1–3 by the intensity of complex II. As in part a, complex I is absent in the Mbd2(−/−) extracts. The R593 antibody produces a specific shift of complex I in wild-type nuclear extract (lanes 2–3), but no shift is observed in nuclear extracts derived from Mbd2(−/−) fibroblasts (lanes 5,6).